/
SRPT
$15.32-$0.56 (-3.52%)live
Held by
1
portfolio on TandT
Bookmarked by
0
users
Avg position size
7.9%
of holders' portfolios
13F filers
2
institutions
Market cap
$1.7B
106M shares
52-week range
$11.68 – $25.32
27% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-53.62
Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
www.sarepta.com- Employees
- 835
- IPO / List date
- Jun 4, 1997
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| July PortfolioShkreli | Mild8% |
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,665,078 | $36.2M |
Recent trades on TradeandTell
- 7/10/2026in July Portfolio →
